Pulmonary fibrosis refers to the loss of control of fibroblasts in the repair process of the lung after damage, which makes the lung tissue harden and gradually lose its ability, is called Idiopathic Pulmonary Fibrosis (IPF). With the backing of the Department of Technology, Ministry of Economic Affairs, DCB has made significant investments in establishing the first domestic platform for the research and production of oligonucleotide drugs. This platform has successfully developed nucleic acid drug synthesis, purification, and analysis technologies, enabling the production of pharmaceutical-grade nucleic acid drugs weighing 100mg with a purity exceeding 90%. Collaborating with Dr. Yang, Kai-Chien from National Taiwan University College of Medicine, DCB has made groundbreaking advancements in the development of a short-chain nucleic acid drug for the treatment of pulmonary fibrosis. Extensive mouse trials have substantiated its efficacy in effectively impeding the progression of the disease. Going forward, the research will continue and progress to clinical trials. The primary objective of this research platform is to advance technology and elevate Taiwan's research capabilities in the field of oligonucleotide drug development, look forward to bringing hope to patients.